Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

Core Insights - Can-Fite BioPharma Ltd. has received FDA approval for compassionate use of its anti-cancer drug Namodenoson for a pancreatic cancer patient in the U.S. [1][3] - Namodenoson is currently undergoing multiple clinical trials, including a pivotal Phase III study for advanced liver cancer and a Phase IIa study for pancreatic cancer [3][5] - The drug has been granted Orphan Drug Designation by the FDA for pancreatic cancer, which may provide market exclusivity for seven years post-approval [4][6] Company Overview - Can-Fite BioPharma is a clinical-stage biotechnology company focused on developing small molecule drugs for oncological and inflammatory diseases [1][6] - The company’s lead drug candidate, Piclidenoson, has recently reported positive results in a Phase III trial for psoriasis [6] - Namodenoson has shown potential efficacy in treating various cancers, including colon, prostate, and melanoma, and has an excellent safety profile based on clinical studies involving over 1,600 patients [5][6]